I undersøgelse III blev patienterne randomiseret til behandling i 26 uger med enten placebo (159 patienter), rasagilin 0, 5 mg dagligt (164 patienter) eller rasagilin 1 mg dagligt (149 patienter).
In study III patients were randomly assigned to receive placebo (159 patients), rasagiline 0.5 mg/ day (164 patients), or rasagiline 1 mg/ day (149 patients), and were treated for 26 weeks.